舒洛地特与辛伐他汀联合治疗糖尿病下肢血管病变的临床疗效

Clinical Efficacy of Sulodexide Combined with Simvastatin in the Treatment of Diabetic Lower Extremity Vascular Disease

目的探讨舒洛地特与辛伐他汀联合治疗糖尿病下肢血管病变的临床疗效。方法将2017年1—12月收治的78例糖尿病下肢血管病变病患,按奇偶法分为参照组39例采用舒洛地特治疗,研究组39例在此基础上联合辛伐他汀治疗。观察比较两组治疗后行走情况、下肢血流学指标情况以及不良反应发生率。结果研究组无痛行走距离(791.92±226.21)m与最大行走距离(997.28±242.82)m均显著长于参照组的(446.78±267.44)m和(731.57±230.56)m(t=6.153,4.956;P<0.05),下肢疼痛评分(3.53±0.89)分显著低于参照组(5.98±1.32分)(t=9.611;P<0.05);病患的血流速度(5.23±1.81)mm/s和搏动指数(9.92±3.24)s均明显快于参照组的(4.15±0.31)mm/s和(7.25±1.87)s(t=4.673,4.457;P<0.05),阻力指数(0.62±0.35)mL/min明显低于参照组的(0.83±0.44)mL/min(t=4.333,P<0.05);不良反应发生率5.13%显著低于参照组的20.51%,差异均有统计学意义(χ~2=4.129,P<0.05)。结论对糖尿病下肢血管病变给予舒洛地特与辛伐他汀联合治疗效果显著,可有效改善病患下肢血流学,缓解下肢疼痛情况,减少不良反应发生率,促进病情康复,具有较高的安全性和临床推广应用价值。

Objective To investigate the clinical efficacy of sulodexide and simvastatin in the treatment of diabetic lower extremity vascular disease. Methods 78 patients with diabetic lower extremity vasculopathy admitted from January to December 2017 were randomly divided into reference group, 39 patients were treated with sulodexide, and 39 patients in the study group were combined with simvastatin statin treatment. Observed and compared the walking condition, blood flow index of the lower limbs and the incidence of adverse reactions. Results The painless walking distance （791.92±226.21）m and the maximum walking distance （997.28±242.82）m of the study group were significantly longer than the reference group （446.78±267.44）m and （731.57±230.56）m （t=6.153, 4.956; P〈0.05）, the lower extremity pain score （3.53±0.89）points was significantly lower than the reference group （5.98±1.32）points （t=9.611; P〈0.05）; the patient＇s blood flow velocity （5.23±1.81）mm/s and pulsatility index （9.92±3.24）s were significantly faster than the reference group （4.15±0.31）mm/s and （7.25±1.87）s （t=4.673, 4.457; P〈0.05）, and the resistance index （0.62±0.35）mL/min was significantly lower than the reference group （0.83±0.44）mL/min （t=4.333, P〈0.05）; the incidence of adverse reactions was 5.13% significantly lower than 20.51% of the reference group, and the difference was statistically significant （χ2=4.129, P〈0.05）. Conclusion The combination of sulodexide and simvastatin is effective in the treatment of diabetic lower extremity vascular disease, which can effectively improve the blood flow of lower limbs, relieve the pain of lower limbs, reduce the incidence of adverse reactions, and promote the recovery of the disease, with high safety and clinical application value.